With the advent of new methods for the study of hemostasis systems, allowing to identify molecular markers of thrombophilia, there is an active discussion about the need and effectiveness of protection against thromboembolic complications during pregnancy. Thrombophilia is a known risk of venous thromboembolism (VTE) during pregnancy. However, at present, the issue of hereditary factors of pregnancy remains controversial. The detection of hereditary defects of the hemostasis system is indicated in those cases when, with a negative result, anticoagulant therapy can be stopped. With the usual miscarriage and the occurrence of antenatal flexibility of the fetus, it is necessary to determine the presence of persistent antiphospholipid antibodies in order to exclude antiphospholipid syndrome (APS), which is a high risk of developing VTE during pregnancy. After analyzing the results of modern clinical studies and recommendations, it can also be concluded that screening for the presence of hereditary defects of the hemostatic system should not be performed in routine clinical practice. in the anamnesis. However, this can be both effective and advisable if the primary warning without previous VTE is in a personal and family history in the presence of common risk factors. A personalized risk assessment and stratification is required, taking into account all factors in each case, when a competent prevention of pregnancy and the postpartum period is required. Low molecular weight heparins, including sodium parnaparin (Fluxum ), are the drugs of choice for the prevention of thromboembolic complications and remain a reliable means of anticoagulant activity in these categories of patients.